Skip to main content
SpringerLink
Log in

Therapy Response Imaging in Sarcoma and Musculoskeletal Malignancies

  • Chapter
  • First Online:
Therapy Response Imaging in Oncology

Part of the book series: Medical Radiology ((Med Radiol Diagn Imaging))

  • 689 Accesses

Abstract

Imaging plays an important role in assessing response to treatment in both primary and metastatic sarcomas. The response of sarcomas to targeted therapies is best exemplified by response of gastrointestinal stromal tumor (GIST) to imatinib. Alternate tumor response criteria, namely Choi criteria, were proposed to overcome limitations of Response Evaluation Criteria In Solid Tumors (RECIST) in interpreting response of GIST to imatinib. These alternate tumor response criteria were subsequently found to have a role in assessing response of non-GIST sarcomas including those treated with conventional chemoradiation therapy. In this chapter, we will discuss in detail the pros and cons of various response criteria in GIST and non-GIST sarcomas.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Al-Absi E, Farrokhyar F, Sharma R, Whelan K, Corbett T, Patel M et al (2010) A systematic review and meta-analysis of oncologic outcomes of pre-versus postoperative radiation in localized resectable soft-tissue sarcoma. Ann Surg Oncol 17(5):1367–1374

    Article  PubMed  Google Scholar 

  • Albertsmeier M, Rauch A, Roeder F, Hasenhutl S, Pratschke S, Kirschneck M et al (2018) External beam radiation therapy for resectable soft tissue sarcoma: a systematic review and meta-analysis. Ann Surg Oncol 25(3):754–767

    Article  PubMed  Google Scholar 

  • Baheti AD, Tirumani SH, Sewatkar R, Shinagare AB, Hornick JL, Ramaiya NH et al (2015) Imaging features of primary and metastatic extremity synovial sarcoma: a single institute experience of 78 patients. Br J Radiol 88(1046):20140608

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL et al (2007) We should desist using RECIST, at least in GIST. J Clin Oncol 25(13):1760–1764

    Article  PubMed  Google Scholar 

  • Bramwell VH, Anderson D, Charette ML (2003) Sarcoma disease site G. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev (3):CD003293

    Google Scholar 

  • Braschi-Amirfarzan M, Keraliya AR, Krajewski KM, Tirumani SH, Shinagare AB, Hornick JL et al (2016) Role of imaging in management of desmoid-type fibromatosis: a primer for radiologists. Radiographics 36(3):767–782

    Article  PubMed  Google Scholar 

  • Canter RJ, Martinez SR, Tamurian RM, Wilton M, Li CS, Ryu J et al (2010) Radiographic and histologic response to neoadjuvant radiotherapy in patients with soft tissue sarcoma. Ann Surg Oncol 17(10):2578–2584

    Article  PubMed  PubMed Central  Google Scholar 

  • Chacon M, Eleta M, Espindola AR, Roca E, Mendez G, Rojo S et al (2015) Assessment of early response to imatinib 800 mg after 400 mg progression by (1)(8)F-fluorodeoxyglucose PET in patients with metastatic gastrointestinal stromal tumors. Future Oncol 11(6):953–964

    Article  CAS  PubMed  Google Scholar 

  • Choi H, Charnsangavej C, de Castro Faria S, Tamm EP, Benjamin RS, Johnson MM et al (2004) CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 183(6):1619–1628

    Article  PubMed  Google Scholar 

  • Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR et al (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25(13):1753–1759

    Article  PubMed  Google Scholar 

  • Cohen MH, Farrell A, Justice R, Pazdur R (2009) Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Oncologist 14(2):174–180

    Article  CAS  PubMed  Google Scholar 

  • Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G et al (2002) Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 8(10):3034–3038

    CAS  PubMed  Google Scholar 

  • Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347(7):472–480

    Article  CAS  PubMed  Google Scholar 

  • Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368(9544):1329–1338

    Article  CAS  PubMed  Google Scholar 

  • Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY et al (2009) Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 27(25):4188–4196

    Article  CAS  PubMed  Google Scholar 

  • Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H et al (2013) Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):295–302

    Article  CAS  PubMed  Google Scholar 

  • Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A et al (2016) Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol 34(8):786–793. Pubmed Central PMCID: 5070559 online at www.jco.org. Author contributions are found at the end of this article

    Article  CAS  PubMed  Google Scholar 

  • Desai J, Shankar S, Heinrich MC, Fletcher JA, Fletcher CD, Manola J et al (2007) Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res 13(18 Pt 1):5398–5405

    Article  CAS  PubMed  Google Scholar 

  • Dimitrakopoulou-Strauss A, Ronellenfitsch U, Cheng C, Pan L, Sachpekidis C, Hohenberger P et al (2017) Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review. Clin Transl Imaging 5(3):183–197

    Article  PubMed  PubMed Central  Google Scholar 

  • Doyle LA (2014) Sarcoma classification: an update based on the 2013 World Health Organization classification of tumors of soft tissue and bone. Cancer 120(12):1763–1774

    Article  PubMed  Google Scholar 

  • ESMO/European Sarcoma Network Working Group (2012) Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7):vii49–vii55

    Google Scholar 

  • Evilevitch V, Weber WA, Tap WD, Allen-Auerbach M, Chow K, Nelson SD et al (2008) Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res 14(3):715–720

    Article  CAS  PubMed  Google Scholar 

  • Garcia del Muro X, Lopez-Pousa A, Martin J, Buesa JM, Martinez-Trufero J, Casado A et al (2005) A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas. Cancer 104(8):1706–1712

    Article  CAS  PubMed  Google Scholar 

  • Garcia-Del-Muro X, Lopez-Pousa A, Maurel J, Martin J, Martinez-Trufero J, Casado A et al (2011 Jun 20) Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol 29(18):2528–2533

    Article  CAS  PubMed  Google Scholar 

  • Gounder MM, Lefkowitz RA, Keohan ML, D’Adamo DR, Hameed M, Antonescu CR et al (2011) Activity of Sorafenib against desmoid tumor/deep fibromatosis. Clin Cancer Res 17(12):4082–4090

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gronchi A, Ferrari S, Quagliuolo V, Broto JM, Pousa AL, Grignani G et al (2017) Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol 18(6):812–822

    Article  CAS  PubMed  Google Scholar 

  • Grosso F, Jones RL, Demetri GD, Judson IR, Blay JY, Le Cesne A et al (2007) Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 8(7):595–602

    Article  CAS  PubMed  Google Scholar 

  • He XD, Zhang YB, Wang L, Tian ML, Liu W, Qu Q et al (2015) Prognostic factors for the recurrence of sporadic desmoid-type fibromatosis after macroscopically complete resection: analysis of 114 patients at a single institution. Eur J Surg Oncol 41(8):1013–1019

    Article  CAS  PubMed  Google Scholar 

  • Holdsworth CH, Badawi RD, Manola JB, Kijewski MF, Israel DA, Demetri GD et al (2007) CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. AJR Am J Roentgenol 189(6):W324–W330

    Article  PubMed  Google Scholar 

  • Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D et al (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344(14):1052–1056

    Article  CAS  PubMed  Google Scholar 

  • Judson I, Radford JA, Harris M, Blay JY, van Hoesel Q, le Cesne A et al (2001) Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 37(7):870–877

    Article  CAS  PubMed  Google Scholar 

  • Kalkmann J, Zeile M, Antoch G, Berger F, Diederich S, Dinter D et al (2012) Consensus report on the radiological management of patients with gastrointestinal stromal tumours (GIST): recommendations of the German GIST Imaging Working Group. Cancer Imaging 12:126–135

    Article  PubMed  PubMed Central  Google Scholar 

  • Kang YK, Ryu MH, Yoo C, Ryoo BY, Kim HJ, Lee JJ et al (2013) Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol 14(12):1175–1182

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kollar A, Jones RL, Stacchiotti S, Gelderblom H, Guida M, Grignani G et al (2017) Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. Acta Oncol 56(1):88–92

    Article  CAS  PubMed  Google Scholar 

  • Levy AD, Manning MA, Al-Refaie WB, Miettinen MM (2017a) Soft-tissue sarcomas of the abdomen and pelvis: radiologic-pathologic features, Part 1—common sarcomas: from the radiologic pathology archives. Radiographics 37(2):462–483

    Article  PubMed  Google Scholar 

  • Levy AD, Manning MA, Miettinen MM (2017b) Soft-tissue sarcomas of the abdomen and pelvis: radiologic-pathologic features, Part 2—uncommon sarcomas. Radiographics 37(3):797–812

    Article  PubMed  Google Scholar 

  • Libertini M, Mitra I, van der Graaf WTA, Miah AB, Judson I, Jones RL et al (2018) Aggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic response. Clin Sarcoma Res 8:13

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Look Hong NJ, Hornicek FJ, Harmon DC, Choy E, Chen YL, Yoon SS et al (2013) Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: a 10-year single institution retrospective study. Eur J Cancer 49(4):875–883

    Article  PubMed  CAS  Google Scholar 

  • Lorigan P, Verweij J, Papai Z, Rodenhuis S, Le Cesne A, Leahy MG et al (2007) Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 25(21):3144–3150

    Article  CAS  PubMed  Google Scholar 

  • Mabille M, Vanel D, Albiter M, Le Cesne A, Bonvalot S, Le Pechoux C et al (2009) Follow-up of hepatic and peritoneal metastases of gastrointestinal tumors (GIST) under Imatinib therapy requires different criteria of radiological evaluation (size is not everything!!!). Eur J Radiol 69(2):204–208

    Article  PubMed  Google Scholar 

  • McAuliffe JC, Hunt KK, Lazar AJ, Choi H, Qiao W, Thall P et al (2009) A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol 16(4):910–919

    Article  PubMed  Google Scholar 

  • Messiou C, Bonvalot S, Gronchi A, Vanel D, Meyer M, Robinson P et al (2016) Evaluation of response after pre-operative radiotherapy in soft tissue sarcomas; the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) and Imaging Group recommendations for radiological examination and reporting with an emphasis on magnetic resonance imaging. Eur J Cancer 56:37–44

    Article  CAS  PubMed  Google Scholar 

  • Miki Y, Ngan S, Clark JC, Akiyama T, Choong PF (2010) The significance of size change of soft tissue sarcoma during preoperative radiotherapy. Eur J Surg Oncol 36(7):678–683

    Article  CAS  PubMed  Google Scholar 

  • Mullen JT, Kobayashi W, Wang JJ, Harmon DC, Choy E, Hornicek FJ et al (2012) Long-term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large, extremity soft tissue sarcomas. Cancer 118(15):3758–3765

    Article  PubMed  Google Scholar 

  • Murphey MD, Gibson MS, Jennings BT, Crespo-Rodriguez AM, Fanburg-Smith J, Gajewski DA (2006) From the archives of the AFIP: imaging of synovial sarcoma with radiologic-pathologic correlation. Radiographics 26(5):1543–1565

    Article  PubMed  Google Scholar 

  • NCCN Clinical Practice Guidelines in Oncology Soft Tissue Sarcoma Version 2 (2018) NCCN; 2018 [12.02.2018]. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site

  • O’Sullivan PJ, Harris AC, Munk PL (2008) Radiological features of synovial cell sarcoma. Br J Radiol 81(964):346–356

    Article  PubMed  Google Scholar 

  • Papagelopoulos PJ, Mavrogenis AF, Mastorakos DP, Patapis P, Soucacos PN (2008) Current concepts for management of soft tissue sarcomas of the extremities. J Surg Orthopaedic Adv 17(3):204–215

    Google Scholar 

  • Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M (2008) A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 113(3):573–581

    Article  PubMed  Google Scholar 

  • Pitson G, Robinson P, Wilke D, Kandel RA, White L, Griffin AM et al (2004) Radiation response: an additional unique signature of myxoid liposarcoma. Int J Radiat Oncol Biol Phys 60(2):522–526

    Article  PubMed  Google Scholar 

  • Recine F, Bongiovanni A, Riva N, Fausti V, De Vita A, Mercatali L et al (2017) Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas. OncoTargets Ther 10:1155–1164

    Article  CAS  Google Scholar 

  • Rezai P, Pisaneschi MJ, Feng C, Yaghmai V (2013) A radiologist’s guide to treatment response criteria in oncologic imaging: anatomic imaging biomarkers. AJR Am J Roentgenol 201(2):237–245

    Article  PubMed  Google Scholar 

  • Roberge D, Skamene T, Nahal A, Turcotte RE, Powell T, Freeman C (2010) Radiological and pathological response following pre-operative radiotherapy for soft-tissue sarcoma. Radiotherapy Oncol 97(3):404–407

    Article  Google Scholar 

  • Robinson E, Bleakney RR, Ferguson PC, O’Sullivan B (2008) Oncodiagnosis panel: 2007: multidisciplinary management of soft-tissue sarcoma. Radiographics 28(7):2069–2086

    Article  PubMed  Google Scholar 

  • Schiavon G, Ruggiero A, Schoffski P, van der Holt B, Bekers DJ, Eechoute K et al (2012) Tumor volume as an alternative response measurement for imatinib treated GIST patients. PloS one 7(11):e48372

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schiavon G, Ruggiero A, Bekers DJ, Barry PA, Sleijfer S, Kloth J et al (2014) The effect of baseline morphology and its change during treatment on the accuracy of Response Evaluation Criteria in Solid Tumours in assessment of liver metastases. Eur J Cancer 50(5):972–980

    Article  PubMed  Google Scholar 

  • Schoffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E et al (2016) Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 387(10028):1629–1637

    Article  CAS  PubMed  Google Scholar 

  • Schramm N, Englhart E, Schlemmer M, Hittinger M, Ubleis C, Becker CR et al (2013) Tumor response and clinical outcome in metastatic gastrointestinal stromal tumors under sunitinib therapy: comparison of RECIST, Choi and volumetric criteria. Eur J Radiol 82(6):951–958

    Article  CAS  PubMed  Google Scholar 

  • Schuetze SM (2006) Utility of positron emission tomography in sarcomas. Curr Opin Oncol 18(4):369–373

    Article  PubMed  Google Scholar 

  • Schuetze SM, Rubin BP, Vernon C, Hawkins DS, Bruckner JD, Conrad EU 3rd et al (2005) Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 103(2):339–348

    Article  PubMed  Google Scholar 

  • Schwab JH, Boland PJ, Antonescu C, Bilsky MH, Healey JH (2007) Spinal metastases from myxoid liposarcoma warrant screening with magnetic resonance imaging. Cancer 110(8):1815–1822

    Article  PubMed  Google Scholar 

  • Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F et al (2017) Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol 18(10):1397–1410

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shankar S, vanSonnenberg E, Desai J, Dipiro PJ, Van Den Abbeele A, Demetri GD (2005) Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology 235(3):892–898

    Article  PubMed  Google Scholar 

  • Sheth PJ, Del Moral S, Wilky BA, Trent JC, Cohen J, Rosenberg AE et al (2016) Desmoid fibromatosis: MRI features of response to systemic therapy. Skelet Radiol 45(10):1365–1373

    Article  Google Scholar 

  • Shinagare AB, Jagannathan JP, Kurra V, Urban T, Manola J, Choy E et al (2014) Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib. Eur J Cancer 50(5):981–986

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shinagare AB, Barysauskas CM, Braschi-Amirfarzan M, O’Neill AC, Catalano PJ, George S et al (2016) Comparison of performance of various tumor response criteria in assessment of sunitinib activity in advanced gastrointestinal stromal tumors. Clin Imaging 40(5):880–884

    Article  PubMed  Google Scholar 

  • Siegel GW, Biermann JS, Chugh R, Jacobson JA, Lucas D, Feng M et al (2015) The multidisciplinary management of bone and soft tissue sarcoma: an essential organizational framework. J Multidiscip Healthc 8:109–115

    PubMed  PubMed Central  Google Scholar 

  • Sood S, Baheti AD, Shinagare AB, Jagannathan JP, Hornick JL, Ramaiya NH et al (2014) Imaging features of primary and metastatic alveolar soft part sarcoma: single institute experience in 25 patients. Br J Radiol 87(1036):20130719

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Stacchiotti S, Collini P, Messina A, Morosi C, Barisella M, Bertulli R et al (2009) High-grade soft-tissue sarcomas: tumor response assessment—pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology 251(2):447–456

    Article  PubMed  Google Scholar 

  • Stacchiotti S, Negri T, Zaffaroni N, Palassini E, Morosi C, Brich S et al (2011) Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. Ann Oncol 22(7):1682–1690

    Article  CAS  PubMed  Google Scholar 

  • Stacchiotti S, Verderio P, Messina A, Morosi C, Collini P, Llombart-Bosch A et al (2012) Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. Cancer 118(23):5857–5866

    Article  PubMed  Google Scholar 

  • Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J et al (2003) 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 39(14):2012–2020

    Article  CAS  PubMed  Google Scholar 

  • Stroszczynski C, Jost D, Reichardt P, Chmelik P, Gaffke G, Kretzschmar A et al (2005) Follow-up of gastro-intestinal stromal tumours (GIST) during treatment with imatinib mesylate by abdominal MRI. Eur Radiol 15(12):2448–2456

    Article  PubMed  Google Scholar 

  • Tang L, Zhang XP, Sun YS, Shen L, Li J, Qi LP et al (2011) Gastrointestinal stromal tumors treated with imatinib mesylate: apparent diffusion coefficient in the evaluation of therapy response in patients. Radiology 258(3):729–738

    Article  PubMed  Google Scholar 

  • Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D et al (2016) Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet 388(10043):488–497

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tirumani SH, Jagannathan JP, Krajewski KM, Shinagare AB, Jacene H, Ramaiya NH (2013) Imatinib and beyond in gastrointestinal stromal tumors: a radiologist’s perspective. AJR Am J Roentgenol 201(4):801–810

    Article  PubMed  Google Scholar 

  • Tirumani SH, Shinagare AB, O’Neill AC, Nishino M, Rosenthal MH, Ramaiya NH (2016) Accuracy and feasibility of estimated tumour volumetry in primary gastric gastrointestinal stromal tumours: validation using semiautomated technique in 127 patients. Eur Radiol 26(1):286–295

    Article  PubMed  Google Scholar 

  • Van den Abbeele AD (ed) (2001) F18-FDG-PET provides early evidence of biological response to STI571 in patients with malignant gastrointestinal stromal tumors (GIST). Proc Am Soc Clin Oncol 20:362a

    Google Scholar 

  • Van den Abbeele AD (2008) The lessons of GIST—PET and PET/CT: a new paradigm for imaging. Oncologist 13(Suppl 2):8–13

    Article  PubMed  Google Scholar 

  • Van den Abbeele A, Badawi R, Tetrault R, Cliche J, Manola J, Spangler T et al (eds) (2003) FDG-PET as a surrogate marker for response to Gleevec (TM)(imatinib mesylate) in patients with advanced gastrointestinal stromal tumors (GIST). J Nucl Med 44:24–25

    Google Scholar 

  • de Vreeze RS, de Jong D, Haas RL, Stewart F, van Coevorden F (2008) Effectiveness of radiotherapy in myxoid sarcomas is associated with a dense vascular pattern. Int J Radiat Oncol Biol Phys 72(5):1480–1487

    Article  PubMed  Google Scholar 

  • Wang WL, Katz D, Araujo DM, Ravi V, Ludwig JA, Trent JC et al (2012) Extensive adipocytic maturation can be seen in myxoid liposarcomas treated with neoadjuvant doxorubicin and ifosfamide and pre-operative radiation therapy. Clin Sarcoma Res 2(1):25

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Wang YF, Guo W, Sun KK, Yang RL, Tang XD, Ji T et al (2015) Postoperative recurrence of desmoid tumors: clinical and pathological perspectives. World J Surg Oncol 13:26

    Article  PubMed  PubMed Central  Google Scholar 

  • Wortman JR, Tirumani SH, Tirumani H, Shinagare AB, Jagannathan JP, Hornick JL et al (2016) Neoadjuvant radiation in primary extremity liposarcoma: correlation of MRI features with histopathology. Eur Radiol 26(5):1226–1234

    Article  PubMed  Google Scholar 

  • Zhao RP, Yu XL, Zhang Z, Jia LJ, Feng Y, Yang ZZ et al (2016) The efficacy of postoperative radiotherapy in localized primary soft tissue sarcoma treated with conservative surgery. Radiat Oncol 11:25

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Imaging, Dana-Farber Cancer Institute/Brigham and Women’s Hospital, Boston, MA, USA

    Sree Harsha Tirumani

  2. Department of Radiology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA

    Sree Harsha Tirumani

Authors
  1. Sree Harsha Tirumani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sree Harsha Tirumani .

Editor information

Editors and Affiliations

  1. Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

    Mizuki Nishino

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Tirumani, S.H. (2020). Therapy Response Imaging in Sarcoma and Musculoskeletal Malignancies. In: Nishino, M. (eds) Therapy Response Imaging in Oncology. Medical Radiology(). Springer, Cham. https://doi.org/10.1007/978-3-030-31171-1_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-31171-1_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-31170-4

  • Online ISBN: 978-3-030-31171-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation